Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Aardvark Therapeutics, Inc. Common Stock logo

Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Ticker

NASDAQ: AARD · Healthcare · Biotechnology
$5.06-8.83%
USD · as of 2026-09-27 · market cap $110.7M
Open AARD in TickrDownload for iPhone

AARD right now

Options price it to move more than 9 in 10 stocks.
Options expect by Oct 6±18.8%
Options expect by Oct 29±38.9%
Priced in for Nov 12 earnings±47.1%
IV rank (30-day)67% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full AARD picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on AARD
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

AARD stock facts

Ticker symbolAARD
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$110.7M
CEOTien-Li Lee
Employees28
HeadquartersSan Diego, CA, US
IPO date2025-02-13
Websiteaardvarktherapeutics.com

What you can see for AARD on Tickr

Live AARD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AARD report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Aardvark Therapeutics, Inc. Common Stock?

The ticker symbol for Aardvark Therapeutics, Inc. Common Stock is AARD, listed on the NASDAQ Global Select.

What is AARD?

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It…

HomeExploreMarketLists
All pages